Pneumocystis Frequently Found Lethal in Dermatomyositis
|
By LabMedica International staff writers Posted on 25 Sep 2021 |
|
Photomicrograph of Pneumocystis jirovecii cysts in stained with Grocott-Gomori Methenamine special silver stain of lung epithelium shows numerous small, disk-shaped organisms (Photo courtesy of Michelle N Kelly, PhD, and Judd E Shellito, MD)
The term idiopathic inflammatory myopathy (IIM) denotes a group of autoimmune diseases characterized by myasthenia and typical skin rash, among which dermatomyositis (DM) and polymyositis (PM) are the most common.
Idiopathic inflammatory myopathies (IIM) are associated with a significantly higher risk of opportunistic infections including Pneumocystis jirovecii pneumonia (PJP), a potentially fatal opportunistic infection. In patients with rheumatic immune diseases, most PJP occurs in the first three months after initiating immunosuppressive therapy.
A team of Rheumatologists at the Renji Hospital (Shanghai, China) prospectively followed 463 consecutive patients with IIM a period of at least one year to analyze the incidence of PJP. In the second part of the study, they enrolled 30 consecutive PJP patients with any rheumatic disease in order to identify the mortality rate and risk factors. The diagnosis of PJP was based on comprehensive evaluation by clinical manifestations such as fever or acute dyspnea, characteristic radiographic findings, and etiological evidence. For confirmation, a case needed to have positive microbiological tests such as by next-generation sequencing and Grocott-Gomori methenamine-silver staining of bronchoalveolar lavage fluid.
The team reported that the prevalence of PJP in IIM patients was found to be 3.0/100 person-years, while in anti-melanoma differentiation-associated gene 5 antibody positive (MDA5+) DM patients it was 7.5/100 person-years and in MDA5− IIM patients 0.7/100 person-years. PJP typically occurred in the first two months in the case of MDA5+ DM patients who had a significant decrease in their CD4+ T cell counts and lymphocyte counts. In PJP patients, 3-month mortality was higher for MDA5+ DM patients than in those with other rheumatic diseases (83.3% versus 38.9%). Worryingly, MDA5+ DM patients seemed not to benefit from prompt anti-PJP treatment, unlike patients with other rheumatic diseases whose survival improved when anti-PJP treatment was started within six days.
The authors concluded that the MDA5+ DM patients are highly susceptible to infection with Pneumocystis jirovecii, which is also harder to cure than in other rheumatic diseases. The reason for the higher incidence and mortality may be related to the lower CD4+ T cell counts and progressive interstitial lung disease in MDA5+ patients. The study was published on September 4, 2021 in the journal Arthritis Research & Therapy.
Related Links:
Renji Hospital
Idiopathic inflammatory myopathies (IIM) are associated with a significantly higher risk of opportunistic infections including Pneumocystis jirovecii pneumonia (PJP), a potentially fatal opportunistic infection. In patients with rheumatic immune diseases, most PJP occurs in the first three months after initiating immunosuppressive therapy.
A team of Rheumatologists at the Renji Hospital (Shanghai, China) prospectively followed 463 consecutive patients with IIM a period of at least one year to analyze the incidence of PJP. In the second part of the study, they enrolled 30 consecutive PJP patients with any rheumatic disease in order to identify the mortality rate and risk factors. The diagnosis of PJP was based on comprehensive evaluation by clinical manifestations such as fever or acute dyspnea, characteristic radiographic findings, and etiological evidence. For confirmation, a case needed to have positive microbiological tests such as by next-generation sequencing and Grocott-Gomori methenamine-silver staining of bronchoalveolar lavage fluid.
The team reported that the prevalence of PJP in IIM patients was found to be 3.0/100 person-years, while in anti-melanoma differentiation-associated gene 5 antibody positive (MDA5+) DM patients it was 7.5/100 person-years and in MDA5− IIM patients 0.7/100 person-years. PJP typically occurred in the first two months in the case of MDA5+ DM patients who had a significant decrease in their CD4+ T cell counts and lymphocyte counts. In PJP patients, 3-month mortality was higher for MDA5+ DM patients than in those with other rheumatic diseases (83.3% versus 38.9%). Worryingly, MDA5+ DM patients seemed not to benefit from prompt anti-PJP treatment, unlike patients with other rheumatic diseases whose survival improved when anti-PJP treatment was started within six days.
The authors concluded that the MDA5+ DM patients are highly susceptible to infection with Pneumocystis jirovecii, which is also harder to cure than in other rheumatic diseases. The reason for the higher incidence and mortality may be related to the lower CD4+ T cell counts and progressive interstitial lung disease in MDA5+ patients. The study was published on September 4, 2021 in the journal Arthritis Research & Therapy.
Related Links:
Renji Hospital
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Steam Sterilizer
Hi Vac II Line
Electrolyte Analyzer
BKE-B
Latest Immunology News
- Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
- Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
- Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
- Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
- Airway Immune Signature May Predict Tuberculosis Progression Risk
- New Cellular Biomarkers Correlate with Disease Severity in Sjögren Disease
- Lung Immune Profiling Reveals Distinct Severe Pneumonia Subtypes
- Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis
- Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
- Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
- Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
- Study Points to Autoimmune Pathway Behind Long COVID Symptoms
- Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
- Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
- Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
- Biomarkers and Molecular Testing Advance Precision Allergy Care
Channels
Clinical Chemistry
view channel
Blood Hormone Pattern Distinguishes Endometriosis with High Accuracy
Endometriosis occurs when tissue similar to the uterine lining grows outside the womb, triggering inflammation, pain, and scarring. Diagnosis often relies on surgery and, in the UK, takes an average of... Read more
Blood Test Brings Alzheimer’s Biomarker Assessment to Routine Labs
Beckman Coulter Diagnostics has received CE Mark under IVDR for the Access p‑Tau217 assay, a blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms... Read more
Molecular Diagnostics
view channel
Epigenetic Profiling Could Refine Prognosis in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with heterogeneous biology that complicates prognostication and treatment selection. Genetic testing clarifies many drivers, yet it... Read more
Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) causes progressive, irreversible lung scarring that limits breathing and can lead to death. More than 100,000 Americans live with IPF, and an estimated 30,000–40,000... Read more
Extracellular Vesicle Marker Identifies Early Lung Adenocarcinoma and Predicts Recurrence
Lung cancer remains a leading cause of cancer death, and early-stage disease often produces few symptoms, complicating timely diagnosis and risk stratification. Conventional imaging and tissue biopsy have... Read more
Hematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read more
Microbiology
view channel
CE-Marked Blood Assay Automates Tuberculosis Infection Testing
Tuberculosis continues to pose a major global health challenge, with an estimated 10.7 million people falling ill and 1.23 million deaths in 2024. Roughly one quarter of the world’s population is believed... Read more
Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
Genomic surveillance is essential for detecting viral variants before they spread widely, yet many public health systems face high costs, uneven capacity, and computational barriers. Existing analytic... Read more
Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
Acute infectious gastroenteritis remains a major cause of illness worldwide, especially in young children, older adults, and immunocompromised patients. Nonspecific symptoms such as diarrhea, vomiting,... Read more
H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read morePathology
view channel
New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
Recurrent breast cancer remains a persistent driver of morbidity and retreatment, and current risk stratification often depends on genomic assays that are costly and slow. Waiting weeks for results can... Read more
EBV Status Helps Predict Survival in Primary CNS Lymphoma
Primary central nervous system lymphoma is a rare malignancy in which tumors arise in the brain and, less often, the spinal cord, eyes, or cerebrospinal fluid. Outcomes are especially variable when the... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more
